Current diabetes and metabolic health news selected for patient safety, public usefulness, novelty, and evidence strength.News posts summarize source material in plain language and include practical takeaways. They are not individualized medical advice and should not replace clinician guidance.
A 15,413-person real-world study linked publicly funded flash glucose monitoring with fewer acute diabetes-related hospitalizations, shorter stays, and lower inpatient costs, but its quasi-experimental design cannot prove that monitoring alone caused the improvements.
A post hoc CANVAS analysis found no clear kidney or cardiovascular advantage for canagliflozin 300 mg over 100 mg, but the findings are hypothesis-generating rather than definitive.
A prespecified VESALIUS-CV analysis found fewer major cardiovascular events with evolocumab in selected adults with high-risk diabetes, but the results are not a recommendation for everyone with diabetes.
A randomized trial found that adding flash glucose monitoring did not improve glycaemic control in gestational diabetes, while a secondary newborn finding needs cautious interpretation.
A randomized trial found that automated insulin delivery improved time in range for adults with diabetes and advanced kidney disease, but long-term benefits remain unknown.
A Lancet Diabetes & Endocrinology consensus statement highlights nutrition, muscle, function, GI symptoms, and psychological support during incretin therapy.